Aleta Biotherapeutics develops CAR T Engagers (CTEs) that enhance the expression of target antigens on cancer cells, improving the efficacy of CAR T cell therapies against B cell malignancies. Their lead product, ALETA-001, aims to increase the percentage of patients achieving complete remission after CD19-targeting CAR T therapy from 45% to over 60%, addressing the high relapse rates in lymphoma and myeloma patients.

The startup offers an alternative asset investment platform that enables everyday investors to utilize their retirement savings for investments in real-world assets through self-directed IRAs. By providing a user-friendly interface, the platform facilitates access to diverse investment opportunities while allowing companies to attract funding from retirement accounts.

AntagomiR develops anti-miR oligonucleotides targeting upregulated microRNAs in myotonic dystrophy patients, addressing the underlying toxic DMPK and insufficient MBNL levels. Their fatty acid-conjugated delivery system enables effective treatment with a significantly reduced active dose directly to muscle tissue.

AUM Biosciences is developing precision oncology therapeutics that utilize multi-faceted inhibition strategies to combat cancer resistance mechanisms. The company targets the challenge of evolving cancer cells that evade treatment, aiming to enhance the effectiveness of existing therapies in the Asian market.

Cocoon provides leave management software that automates compliance with FMLA and state leave laws, streamlining claims processing and payroll calculations for HR teams. By reducing administrative workload, Cocoon saves organizations an average of $12,515 per leave in recouped benefits payments while enhancing the employee experience with a user-friendly interface for planning and tracking leave.

Covid Solutions offers integrated health and safety management for businesses, providing COVID-19 testing, PPE, and intelligent access control systems with temperature screening and facial recognition. They also deliver environmental disinfection and occupational health programs to ensure workplace safety and operational continuity.

Develops a Microcycle® platform that enables direct screening of small molecule libraries within mammalian cells, facilitating the discovery of biologically active compounds. This approach targets complex disease mechanisms, such as challenging cancer targets, that are often inaccessible to traditional drug discovery methods.

Integra Therapeutics develops gene writing tools that combine CRISPR-Cas precision with engineered piggybac transposase for efficient delivery of both small and large DNA payloads. The technology addresses limitations in gene therapy related to gene size, precision, and stability, aiming to cure genetic and oncological diseases with high unmet medical needs.

Jurata provides thermostable formulation technologies that keep biologic APIs active at ambient or elevated temperatures, eliminating the need for cold‑chain logistics. Their platform supports both liquid and thin‑film formats for a range of delivery routes, including injectable and needle‑free options, and is compatible with vaccines, gene therapies, antibodies, proteins, and peptides. This enables pharmaceutical and biotech developers to simplify manufacturing, reduce shipping costs, and expand product access worldwide.

The startup develops a proprietary B-Raf inhibitor, a small molecule that enhances the administration of epidermal growth factor receptor (EGFR) inhibitors in cancer therapy. This approach minimizes cutaneous side effects, thereby improving treatment effectiveness and the quality of life for patients undergoing EGFR therapy.

MapLight Therapeutics utilizes optogenetics, STARmap, and transcriptomics to identify and target specific neural circuits involved in brain disorders. The company aims to develop therapeutics that provide effective treatment options for conditions such as schizophrenia, Alzheimer’s disease psychosis, and autism spectrum disorder, addressing the limitations of current therapies.

MiNK Therapeutics develops allogeneic invariant natural killer T (iNKT) cell therapies for cancer and immune-mediated diseases, utilizing a dual-mechanism approach that combines the cytotoxicity of natural killer cells with the memory response of T cells. Their off-the-shelf therapy, which does not require lymphodepletion or HLA matching, aims to improve patient outcomes in solid tumors and acute respiratory distress syndrome.

Nereid Therapeutics utilizes proprietary technologies to measure and visualize liquid-liquid phase separation (LLPS) in mammalian cells, enabling the discovery of small molecules that can modulate protein interactions involved in diseases like cancer and inflammatory disorders. By providing precise insights into biomolecular condensates, the company addresses the challenge of developing effective treatments for intractable diseases that have limited therapeutic options.

Ratio Therapeutics develops targeted radiopharmaceuticals using its proprietary Trillium™ targeting scaffold, which combines pharmacokinetic modulation with advanced chelation technology to enhance the delivery of therapeutic agents. The company addresses the need for effective treatments for solid tumors, including breast, pancreatic, lung, and colon cancers, by enabling precise imaging and therapeutic applications through its theranostic platform.

Sania Therapeutics is developing precision gene therapies that utilize targeted delivery systems to treat prevalent nervous system disorders. Their approach aims to enhance therapeutic control and efficacy, addressing the unmet medical needs in this underserved area.

Tolerance Bio is developing therapies that manipulate immune tolerance by preserving and restoring thymus function, which is critical for regulating immune responses. The company targets immune-mediated diseases, aiming to enhance health span through thymus-based interventions.

The startup offers a pet consultation platform that connects pet owners with licensed veterinarians to provide tailored advice based on individual pet profiles and budget considerations. By utilizing a data-driven approach, the platform ensures that users receive specific and actionable recommendations for their pets' health and well-being.